Polymorphism in ion channel genes of Dirofilaria immitis: Relevant knowledge for future anthelmintic drug design

Thangadurai Mani1, Catherine Bourguinat1, Kathy Keller1

  • 1Institute of Parasitology, McGill University, 21111 Lakeshore Road, Sainte-Anne-de-Bellevue, QC H9X 3V9, Canada.

Insights

New research identifies genetic variations in heartworm ion channels, crucial for developing novel anthelmintics to combat drug resistance in Dirofilaria immitis.

Area of Science:

  • Veterinary Parasitology
  • Molecular Biology
  • Drug Discovery

Background:

  • Dirofilaria immitis causes cardiopulmonary dirofilariasis in animals.
  • Macrocyclic lactone (ML) drugs are used for prevention, but resistance is confirmed.
  • New anthelmintics targeting ion channels are urgently needed.

Purpose of the Study:

  • To analyze genetic variability in Dirofilaria immitis ion channel and receptor genes.
  • To identify potential targets for new anthelmintic drug design.
  • To inform strategies for overcoming ML resistance.

Main Methods:

  • Whole genome sequencing of D. immitis from eight geographical locations (ML-susceptible and ML-loss of efficacy populations).
  • Polymorphism analysis of 224 identified ion channel genes/subunits.
  • Identification and characterization of single nucleotide polymorphisms (SNPs).

Main Results:

  • Identified 1762 SNPs across 224 ion channel genes/subunits (0.18% polymorphic rate).
  • Found 129 non-synonymous exonic SNPs, with 14 altering predicted secondary structure.
  • Detected SNPs potentially impacting gene expression, protein function, and resistance.

Conclusions:

  • Genetic variability in ion channel genes provides valuable data for novel drug design against Dirofilaria immitis.
  • Understanding these polymorphisms can aid in predicting and managing anthelmintic resistance.
  • Targeting ion channels remains a promising strategy for developing effective heartworm treatments.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
93